Frontier Labs Want to Slow Down, OpenAI Delays Its 2026 IPO, Anthropic Flags 5 Bioweapon Cases | EP #291

The recent surge in AI capability and the subsequent push for industry-wide regulation have triggered a high-stakes debate regarding the future of superintelligence. Industry leaders, including Anthropic’s Dario Amadei and OpenAI’s Sam Altman, have advocated for pacing the development of frontier models to prioritize safety, a move critics characterize as a "safety cartel" aimed at regulatory capture. While some argue that defensive co-scaling and rigorous independent testing are essential to mitigate risks like bioweapon development, others view these calls for deceleration as a moral panic amplified by foreign state actors to hinder American technological competitiveness. Ultimately, the industry faces a tension between the existential risks of unaligned AI and the massive potential for solving global challenges, with experts emphasizing that true progress requires balancing safety protocols with the rapid, ethical advancement of AI-driven innovation.